不同化疗方案治疗多发性骨髓瘤患者的效果比较
发布时间：2018-11-20 11:08
【摘要】：目的:比较T-VD方案(硼替佐米+地塞米松+沙利度胺)与T-VAD方案(长春新碱+阿霉素+地塞米松+沙利度胺)治疗多发性骨髓瘤(multiple myeloma,MM)的临床效果。方法:选取2010年4月至2012年4月本院收治的30例行T-VD方案化疗的MM患者(T-VD组)和30例行T-VAD方案化疗的MM患者(对照组)作为研究对象,对比2组患者化疗效果及远期生存情况。结果:T-VD组CR率和ORR明显高于T-VAD组(P0.05);T-VD组非轻链型与轻链型患者ORR均明显高于T-VAD组(P0.05);T-VD组非轻链型与轻链型患者ORR对比,差异无统计学意义(P0.05);T-VAD组非轻链型与轻链型患者ORR对比,差异无统计学意义(P0.05);T-VD组Ⅰ-Ⅱ期患者ORR与T-VAD组Ⅰ-Ⅱ期患者对比无显著差异(P0.05);T-VD组Ⅲ期患者ORR明显高于T-VAD组Ⅲ期患者(P0.05);T-VD组Ⅰ-Ⅱ期患者ORR与Ⅲ期患者对比,差异无统计学意义(P0.05);T-VAD组Ⅰ-Ⅱ期患者ORR明显高于Ⅲ期患者(P0.05);T-VD组患者化疗后血清M蛋白、骨髓瘤细胞、β2-MG水平均明显低于T-VAD组(P0.05);T-VD组患者的感染和周围神经病变发生率及无进展生存时间均明显高于对照组(P0.05)。结论:T-VD方案治疗MM患者的效果优于T-VAD方案,且其效果不受分型与分期影响,但会加重部分毒副作用,临床需谨慎选择。
[Abstract]:Objective: to compare the clinical effects of T-VD regimen (bortezomil dexamethasone thalidomide) and T-VAD regimen (vincristine adriamycin dexamethasone thalidomide) in the treatment of multiple myeloma (multiple myeloma,MM). Methods: from April 2010 to April 2012, 30 MM patients treated with T-VD regimen chemotherapy (T-VD group) and 30 MM patients with T-VAD regimen chemotherapy (control group) were selected as the study subjects. The effect of chemotherapy and long-term survival were compared between the two groups. Results: the rate of CR and ORR in T-VD group was significantly higher than that in T-VAD group (P0.05), ORR in T-VD group was significantly higher than that in T-VAD group (P0.05). There was no significant difference in ORR between non-light chain type and light chain type in T-VD group (P0.05), and there was no significant difference in ORR between non-light chain type and light chain type in T-VAD group (P0.05). There was no significant difference between ORR and T-VAD in stage 鈪，
本文编号：2344742
[Abstract]:Objective: to compare the clinical effects of T-VD regimen (bortezomil dexamethasone thalidomide) and T-VAD regimen (vincristine adriamycin dexamethasone thalidomide) in the treatment of multiple myeloma (multiple myeloma,MM). Methods: from April 2010 to April 2012, 30 MM patients treated with T-VD regimen chemotherapy (T-VD group) and 30 MM patients with T-VAD regimen chemotherapy (control group) were selected as the study subjects. The effect of chemotherapy and long-term survival were compared between the two groups. Results: the rate of CR and ORR in T-VD group was significantly higher than that in T-VAD group (P0.05), ORR in T-VD group was significantly higher than that in T-VAD group (P0.05). There was no significant difference in ORR between non-light chain type and light chain type in T-VD group (P0.05), and there was no significant difference in ORR between non-light chain type and light chain type in T-VAD group (P0.05). There was no significant difference between ORR and T-VAD in stage 鈪，
本文编号：2344742
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2344742.html
